Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN
 

Intellectual Property

Covid-19

Drug and chemical firms relax patent controls for COVID-19 response

Gilead offers royalty-free licenses on remdesivir, consortium pledges not to prosecute IP violations done to fight the pandemic

by Craig A. Bettenhausen
May 15, 2020 | A version of this story appeared in Volume 98, Issue 19

Article:

This article has been sent to the following recipient: